GlucoTrack (NASDAQ:GCTK) Announces Quarterly Earnings Results

GlucoTrack (NASDAQ:GCTK) released its quarterly earnings data on Friday. The company reported $0.76 earnings per share (EPS) for the quarter, FiscalAI reports.

GlucoTrack Stock Up 0.5%

NASDAQ GCTK traded up $0.00 during trading on Friday, reaching $0.37. 591,530 shares of the company’s stock traded hands, compared to its average volume of 6,399,748. GlucoTrack has a 12-month low of $0.25 and a 12-month high of $14.14. The firm has a market cap of $2.84 million, a price-to-earnings ratio of -0.02 and a beta of 0.70. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.85 and a quick ratio of 0.85. The company’s 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $0.88.

Institutional Investors Weigh In On GlucoTrack

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in shares of GlucoTrack by 102,125.0% during the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after acquiring an additional 4,085 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of GlucoTrack in the 4th quarter valued at $52,000. Finally, Ikarian Capital LLC purchased a new position in GlucoTrack during the 4th quarter worth approximately $177,000. 10.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on GCTK shares. Wall Street Zen upgraded shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.